336 related articles for article (PubMed ID: 27582545)
1. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
2. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.
Paugh BS; Zhu X; Qu C; Endersby R; Diaz AK; Zhang J; Bax DA; Carvalho D; Reis RM; Onar-Thomas A; Broniscer A; Wetmore C; Zhang J; Jones C; Ellison DW; Baker SJ
Cancer Res; 2013 Oct; 73(20):6219-29. PubMed ID: 23970477
[TBL] [Abstract][Full Text] [Related]
3. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Paugh BS; Qu C; Jones C; Liu Z; Adamowicz-Brice M; Zhang J; Bax DA; Coyle B; Barrow J; Hargrave D; Lowe J; Gajjar A; Zhao W; Broniscer A; Ellison DW; Grundy RG; Baker SJ
J Clin Oncol; 2010 Jun; 28(18):3061-8. PubMed ID: 20479398
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
[TBL] [Abstract][Full Text] [Related]
5. Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ.
Howley R; Kinsella P; Buckley PG; Alcock L; Jansen M; Heffernan J; Stallings RL; Brett FM; Amberger-Murphy V; Farrell MA
Exp Cell Res; 2012 Oct; 318(17):2245-56. PubMed ID: 22705586
[TBL] [Abstract][Full Text] [Related]
6. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.
Miklja Z; Yadav VN; Cartaxo RT; Siada R; Thomas CC; Cummings JR; Mullan B; Stallard S; Paul A; Bruzek AK; Wierzbicki K; Yang T; Garcia T; Wolfe I; Leonard M; Robertson PL; Garton HJ; Wahl DR; Parmar H; Sarkaria JN; Kline C; Mueller S; Nicolaides T; Glasser C; Leary SE; Venneti S; Kumar-Sinha C; Chinnaiyan AM; Mody R; Pai MP; Phoenix TN; Marini BL; Koschmann C
J Clin Invest; 2020 Oct; 130(10):5313-5325. PubMed ID: 32603316
[TBL] [Abstract][Full Text] [Related]
7. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
Barrow J; Adamowicz-Brice M; Cartmill M; MacArthur D; Lowe J; Robson K; Brundler MA; Walker DA; Coyle B; Grundy R
Neuro Oncol; 2011 Feb; 13(2):212-22. PubMed ID: 21138945
[TBL] [Abstract][Full Text] [Related]
8. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
[TBL] [Abstract][Full Text] [Related]
9. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.
Martinho O; Longatto-Filho A; Lambros MB; Martins A; Pinheiro C; Silva A; Pardal F; Amorim J; Mackay A; Milanezi F; Tamber N; Fenwick K; Ashworth A; Reis-Filho JS; Lopes JM; Reis RM
Br J Cancer; 2009 Sep; 101(6):973-82. PubMed ID: 19707201
[TBL] [Abstract][Full Text] [Related]
10. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
11. In vitro neurosphere formation correlates with poor survival in glioma.
C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S
IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962
[TBL] [Abstract][Full Text] [Related]
12. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
15. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Varlet P; Le Teuff G; Le Deley MC; Giangaspero F; Haberler C; Jacques TS; Figarella-Branger D; Pietsch T; Andreiuolo F; Deroulers C; Jaspan T; Jones C; Grill J
Neuro Oncol; 2020 Jan; 22(1):116-127. PubMed ID: 31419298
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R
J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622
[TBL] [Abstract][Full Text] [Related]
17. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.
Chen D; Persson A; Sun Y; Salford LG; Nord DG; Englund E; Jiang T; Fan X
PLoS One; 2013; 8(4):e61556. PubMed ID: 23630597
[TBL] [Abstract][Full Text] [Related]
18. CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high‑grade glioma.
Wang K; Huang R; Li G; Zeng F; Zhao Z; Liu Y; Hu H; Jiang T
Oncol Rep; 2018 Oct; 40(4):2036-2046. PubMed ID: 30066946
[TBL] [Abstract][Full Text] [Related]
19. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
